Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.

BMJ open·2024
Same author

WHO Essential Medicines List and methylphenidate for ADHD in children and adolescents.

The lancet. Psychiatry·2024
Same author

Concentrations, Number of Doses, and Formulations of Aluminium Adjuvants in Vaccines: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Vaccines·2023
Same author

Ugeskrift for laeger·2023
Same author

Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants.

Trials·2023
Same author

The effects of cerebral oximetry in mechanically ventilated newborns: a protocol for the SafeBoosC-IIIv randomised clinical trial.

Trials·2023

Related Experiment Videos

Ursodeoxycholic acid for primary biliary cirrhosis.

Yan Gong1, Zhi Bi Huang, Erik Christensen

  • 1Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen N, Denmark, 2200. ygong@ctu.rh.dk

The Cochrane Database of Systematic Reviews
|August 5, 2008
PubMed
Summary

Ursodeoxycholic acid (UDCA) does not improve survival in primary biliary cirrhosis patients. While some biochemical markers may improve, UDCA is associated with adverse events like weight gain.

Related Experiment Videos

Area of Science:

  • Hepatology
  • Autoimmune Diseases
  • Clinical Trials

Background:

  • Primary biliary cirrhosis (PBC) is a rare autoimmune liver disease with an unclear cause.
  • Ursodeoxycholic acid (UDCA) is a treatment for PBC, but its effectiveness is debated.

Purpose of the Study:

  • To assess the benefits and harms of Ursodeoxycholic acid (UDCA) compared to placebo or no intervention in patients with primary biliary cirrhosis.
  • To analyze the impact of UDCA on mortality, liver transplantation rates, and other clinical outcomes.

Main Methods:

  • Systematic review and meta-analysis of 16 randomized clinical trials involving UDCA for primary biliary cirrhosis.
  • Searched multiple databases including Cochrane Hepato-Biliary Group Register, MEDLINE, and EMBASE up to January 2007.
  • Investigated UDCA effects using meta-regression and Bayesian meta-analytic approaches, assessing risk of bias.

Main Results:

  • No significant improvement in mortality or the combined endpoint of mortality or liver transplantation with UDCA.
  • UDCA did not improve symptoms like pruritus or fatigue, nor did it affect liver histology or portal pressure.
  • While UDCA showed potential improvement in biochemical markers, ascites, and jaundice, these findings were based on limited data and associated with adverse events, primarily weight gain.

Conclusions:

  • This systematic review found no evidence that Ursodeoxycholic acid (UDCA) improves survival in primary biliary cirrhosis patients.
  • Observed minor beneficial effects on biochemical variables were not robust and outweighed by the risk of adverse events.
  • Further research is needed to clarify the role of UDCA in managing primary biliary cirrhosis.